Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.

Saved in:
Bibliographic Details
Title: Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
Authors: Lebwohl D; Novartis Pharmaceuticals Corporation, Florham Park, New Jersey 07932, USA. david.lebwohl@novartis.com, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W
Source: Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2013 Jul; Vol. 1291, pp. 14-32. Date of Electronic Publication: 2013 May 09.
Publication Type: Journal Article; Review
Journal Info: Publisher: New York Academy of Sciences Country of Publication: United States NLM ID: 7506858 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1749-6632 (Electronic) Linking ISSN: 00778923 NLM ISO Abbreviation: Ann N Y Acad Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1749-6632
DOI:10.1111/nyas.12122